PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 488
- Registration Number
- NCT00650039
- Locations
- 🇨🇦
Pfizer Investigational Site, Weston, Ontario, Canada
A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 154
- Registration Number
- NCT00649415
- Locations
- 🇧🇷
Pfizer Investigational Site, São Paulo, Brazil
A Study To Evaluate The Efficacy Of Eplerenone Compared With Losartan For The Treatment Of Patients With Mild To Moderate Hypertension
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2009-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 248
- Registration Number
- NCT00649311
- Locations
- 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan
Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients
Phase 4
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-07-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 489
- Registration Number
- NCT00650455
- Locations
- 🇨🇦
Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada
A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring
Phase 3
Completed
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2008-03-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00646880
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
A Study Of Diflucan In Children With Ringworm Of The Scalp
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 185
- Registration Number
- NCT00645242
- Locations
- 🇵🇷
Pfizer Investigational Site, Ponce, Puerto Rico
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT00644969
- Locations
- 🇨🇦
Pfizer Investigational Site, Toronto, Ontario, Canada
Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2009-09-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00645463
- Locations
- 🇺🇸
Pfizer Investigational Site, Ann Arbor, Michigan, United States
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2009-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00645021
- Locations
- 🇺🇸
Pfizer Investigational Site, Orlando, Florida, United States
Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2009-08-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00644839
- Locations
- 🇺🇸
Pfizer Investigational Site, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath